First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
- Written by PR Newswire Asia - Asian Spectator
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease
Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90%
SYDNEY, April 15, 2024 /PRNewswire/ -- Actinogen Medical...